Pre-earnings options volume in Coherus BioSciences is 1.4x normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 21.5%, or 51c, after results are released. Median move over the past eight quarters is 12.0%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CHRS:
- Options Volatility and Implied Earnings Moves Today, March 13, 2024
- Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
- Sandoz acquires CIMERLI business from Coherus BioSciences
- Coherus Biosciences (CHRS) Q4 Earnings Cheat Sheet
- Coherus Completes Divestiture of Ophthalmology Franchise